Selecta Imm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Selecta Imm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Selecta Imm Today - Breaking & Trending Today

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

Published: October 31, 2023

31.10.2023 - WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) - Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, ... Seite 1

Source: wallstreet-online.de

Selecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 Treatment

Published: October 31, 2023

By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine...

Source: marketwatch.com

FDA Approval of New Gout Drug Likely, Analyst Says

Published: March 28, 2023

FDA Approval of New Gout Drug Likely, Analyst Says

Source: investorideas.com

$Sobi, Selecta: Phase 3 DISSOLVE Program Of SEL-212 In Chronic Refractory Gout Meets Primary Goal - Vimarsana News$

Sobi, Selecta: Phase 3 DISSOLVE Program Of SEL-212 In Chronic Refractory Gout Meets Primary Goal

Published: March 22, 2023

Swedish Orphan Biovitrum AB or Sobi (SWTUY.PK), a specialised biopharmaceutical company, and Selecta Biosciences, Inc. (SELB) announced Tuesday positive topline results from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout.

Source: rttnews.com